Children's Cancer Fund brings world-class pediatric cancer specialist to Dallas

December 05, 2001

DALLAS - Dec. 5, 2001 - The Children's Cancer Fund of Dallas, now in its 19th year of supporting laboratory and clinical research, has helped bring one of the world's most promising young pediatric hematologist/oncologists to UT Southwestern Medical Center at Dallas.

A special Children's Cancer Fund grant of $525,000, added to previously donated funds, will provide four years of start-up research support for Dr. Scott Cameron. A board-certified pediatric oncologist, Cameron comes to Dallas from the Dana Farber Cancer Institute at Harvard. His research probes the fundamental mechanisms of cell growth, differentiation and death, and the links between nature's programmed cell death and cancer.

"Cameron is a first-class pediatrician, molecular biologist and cancer specialist, and he will augment UT Southwestern's core of internationally known oncologists and basic scientists already studying the cellular and molecular causes of cancer," said Dr. George Buchanan, professor of pediatrics and director of the university's pediatric cancer program within the Harold C. Simmons Comprehensive Cancer Center. Buchanan has also been a beneficiary of the Children's Cancer Fund's generosity as holder of the Children's Cancer Fund Distinguished Chair in Pediatric Oncology and Hematology, established in 1993.

In addition to his position as assistant professor in both pediatrics and molecular biology at UT Southwestern, Cameron will also be an attending physician at Children's Medical Center of Dallas.

"We're very excited about Dr. Cameron coming aboard to enhance cancer research at UT Southwestern and treatment of cancer patients at Children's Medical Center," said Dr. William S. Edell, president of Children's Cancer Fund. The organization was formed in 1982 by parents of children being treated for cancer at Children's Medical Center under the care of UT Southwestern physicians.

In February 2000, the Children's Cancer Fund provided a $2 million challenge gift to UT Southwestern to create a $6 million comprehensive pediatric-cancer research center. The gift was the largest single research pledge in the fund's 18-year history. Additional gifts and pledges from other donors totaling $3 million have been received to date.

Other programs supported by Children's Cancer Fund include clinical trials for new leukemia therapies, development of new treatments to reduce the side effects and the costs of chemotherapy and radiation treatments, molecular studies of liver and kidney tumors, and training of young pediatricians to become blood and cancer specialists.

"The Children's Cancer Fund has been a critically important partner of UT Southwestern and Children's Medical Center in our efforts to provide state-of-the-art care for children with cancer and to conduct cutting-edge research that will lead to prevention and cures," said UT Southwestern president Dr. Kern Wildenthal. "We are thrilled that the Children's Cancer Fund's most recent gift will launch the career of such a gifted clinician/scientist as Dr. Cameron."

Cameron graduated from the Health Sciences and Technology Program at MIT/Harvard Medical School and earned a doctorate in genetics from the State University of New York at Stony Brook. He completed an internship and residency in pediatrics at Children's Hospital in Boston and a fellowship in pediatric hematology/oncology at the Dana Farber Cancer Institute.

He has received young investigator awards from the Howard Hughes Medical Institute and the Merck/Massachusetts Institute of Technology Collaborative Program.
To automatically receive news releases from UT Southwestern via e-mail, send a message to Leave the subject line blank and in the text box, type SUB UTSWNEWS.

UT Southwestern Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to